AstraZeneca (LON:AZN) received a GBX 9,000 ($117.59) target price from analysts at Credit Suisse Group in a research note issued to investors on Monday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would suggest a potential upside of 17.97% from the stock’s current price.
AZN has been the subject of several other reports. The Goldman Sachs Group set a GBX 6,800 ($88.84) price objective on shares of AstraZeneca and gave the company a “sell” rating in a report on Friday, April 30th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a £102 ($133.26) price target on shares of AstraZeneca in a report on Thursday, April 8th. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, February 24th. Jefferies Financial Group set a GBX 8,850 ($115.63) target price on shares of AstraZeneca and gave the company a “buy” rating in a report on Friday, April 30th. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Monday, April 26th. Four equities research analysts have rated the stock with a sell rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of GBX 8,886.25 ($116.10).
LON AZN opened at GBX 7,629 ($99.67) on Monday. The stock’s 50-day moving average price is GBX 7,333 and its 200-day moving average price is GBX 7,569.54. The company has a market capitalization of £100.15 billion and a P/E ratio of 34.76. AstraZeneca has a 52 week low of GBX 6,736 ($88.01) and a 52 week high of £101.20 ($132.22). The company has a quick ratio of 0.67, a current ratio of 0.87 and a debt-to-equity ratio of 155.65.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Featured Article: Different Options Trading Strategies
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.